Indication
KIT
1 clinical trial
2 products
Clinical trial
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-12-13
Product
ImatinibProduct
Ipilimumab